Target-specific Delivery of Doxorubicin to Human Glioblastoma Cell Line Via SsDNA Aptamer

Overview

Journal J Biosci

Specialties Biochemistry
Biology

Date 2018 Feb 28

PMID 29485118

Citations 7

Authors

Abdullah Tahir Bayrac

Oya Ercan Akca

Fusun Inci Eyidogan

Huseyin Avni Oktem

Affiliations

Soon will be listed here.

Abstract

Targeted drug delivery approaches have been implementing significant therapeutic gain for cancer treatment since last decades. Aptamers are one of the mostly used and highly selective targeting agents for cancer cells. Herein, we address a nano-sized targeted drug delivery approach adorned with A-172 glioblastoma cell-line-specific single stranded DNA (ssDNA) aptamer in which the chemotherapeutic agent Doxorubicin (DOX) had been conjugated. DNA aptamer, GMT-3, was previously selected for specific recognition of glioblastoma and represented many advantageous characteristics for drug targeting purposes. Flow cytometry analysis proved the binding efficiency of the specific aptamer to tumour cell lines. Celltype- specific toxicity of GMT-3:DOX complex was showed by XTT assay and terminated cytotoxic effects were screened for both target cell and a control breast cancer cell line. The result of this contribution demonstrated the potential utility of GMT-3 aptamer-mediated therapeutic drug transportation in the treatment of gliomas specifically. It was concluded that aptamer-mediated drug delivery can be applied successfully for clinical use.

Citing Articles

Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?.

Giles B, Nakhjavani M, Wiesa A, Knight T, Shigdar S, Samarasinghe R Cancers (Basel). 2023; 15(17).

PMID: 37686652 PMC: 10487158. DOI: 10.3390/cancers15174376.

Calotropis gigantea stem bark extracts inhibit liver cancer induced by diethylnitrosamine.

Sawong S, Pekthong D, Suknoppakit P, Winitchaikul T, Kaewkong W, Somran J Sci Rep. 2022; 12(1):12151.

PMID: 35840761 PMC: 9287404. DOI: 10.1038/s41598-022-16321-0.

Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma.

Cesarini V, Scopa C, Silvestris D, Scafidi A, Petrera V, Del Baldo G Molecules. 2020; 25(18).

PMID: 32957732 PMC: 7570863. DOI: 10.3390/molecules25184267.

The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature.

Nuzzo S, Brancato V, Affinito A, Salvatore M, Cavaliere C, Condorelli G Cancers (Basel). 2020; 12(8).

PMID: 32764266 PMC: 7463716. DOI: 10.3390/cancers12082173.

Nano-Therapies for Glioblastoma Treatment.

Alphandery E Cancers (Basel). 2020; 12(1).

PMID: 31963825 PMC: 7017259. DOI: 10.3390/cancers12010242.

References

Hernandez F, Hernandez L, Pinto A, Schafer T, Ozalp V . Targeting cancer cells with controlled release nanocapsules based on a single aptamer. Chem Commun (Camb). 2013; 49(13):1285-7. DOI: 10.1039/c2cc37370j. View

Han K, Chen S, Chen W, Lei Q, Liu Y, Zhuo R . Synergistic gene and drug tumor therapy using a chimeric peptide. Biomaterials. 2013; 34(19):4680-9. DOI: 10.1016/j.biomaterials.2013.03.010. View

Healy J, Lewis S, Kurz M, Boomer R, Thompson K, Wilson C . Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res. 2005; 21(12):2234-46. DOI: 10.1007/s11095-004-7676-4. View

Hou L, Veeravagu A, Hsu A, Tse V . Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus. 2006; 20(4):E5. DOI: 10.3171/foc.2006.20.4.2. View

Silva E, Bazoni R, Ramos E, Rocha M . DNA-doxorubicin interaction: New insights and peculiarities. Biopolymers. 2016; 107(3). DOI: 10.1002/bip.22998. View

Hughes T, Langer S, Johnson K, Chavez R, Watkins L, Milligan E . Intrathecal injection of naked plasmid DNA provides long-term expression of secreted proteins. Mol Ther. 2008; 17(1):88-94. PMC: 2834984. DOI: 10.1038/mt.2008.230. View

Akkus Sut P, Tunc C, Culha M . Lactose-modified DNA tile nanostructures as drug carriers. J Drug Target. 2016; 24(8):709-19. DOI: 10.3109/1061186X.2016.1144059. View

Zadeh J, Steenberg C, Bois J, Wolfe B, Pierce M, Khan A . NUPACK: Analysis and design of nucleic acid systems. J Comput Chem. 2010; 32(1):170-3. DOI: 10.1002/jcc.21596. View

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

10.

Min K, Jo H, Song K, Cho M, Chun Y, Jon S . Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials. 2010; 32(8):2124-32. DOI: 10.1016/j.biomaterials.2010.11.035. View

11.

Pasquier E, Kavallaris M, Andre N . Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010; 7(8):455-65. DOI: 10.1038/nrclinonc.2010.82. View

12.

Bray F, Jemal A, Grey N, Ferlay J, Forman D . Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012; 13(8):790-801. DOI: 10.1016/S1470-2045(12)70211-5. View

13.

Whitesell L, Geselowitz D, Chavany C, Fahmy B, Walbridge S, Alger J . Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc Natl Acad Sci U S A. 1993; 90(10):4665-9. PMC: 46573. DOI: 10.1073/pnas.90.10.4665. View

14.

Tang Z, Shangguan D, Wang K, Shi H, Sefah K, Mallikratchy P . Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem. 2007; 79(13):4900-7. DOI: 10.1021/ac070189y. View

15.

Kotula J, Pratico E, Ming X, Nakagawa O, Juliano R, Sullenger B . Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther. 2012; 22(3):187-95. PMC: 3423875. DOI: 10.1089/nat.2012.0347. View

16.

Cerchia L, Esposito C, Jacobs A, Tavitian B, de Franciscis V . Differential SELEX in human glioma cell lines. PLoS One. 2009; 4(11):e7971. PMC: 2776989. DOI: 10.1371/journal.pone.0007971. View

17.

Monaco I, Camorani S, Colecchia D, Locatelli E, Calandro P, Oudin A . Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier. J Med Chem. 2017; 60(10):4510-4516. DOI: 10.1021/acs.jmedchem.7b00527. View

18.

Cho K, Wang X, Nie S, Chen Z, Shin D . Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008; 14(5):1310-6. DOI: 10.1158/1078-0432.CCR-07-1441. View

19.

Chon S, Champion R, Geddes E, Rashid R . Chemotherapy-induced alopecia. J Am Acad Dermatol. 2011; 67(1):e37-47. DOI: 10.1016/j.jaad.2011.02.026. View

20.

Sehedic D, Cikankowitz A, Hindre F, Davodeau F, Garcion E . Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. Trends Pharmacol Sci. 2015; 36(4):236-52. DOI: 10.1016/j.tips.2015.02.002. View